These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33055190)

  • 1. Uric Acid and CKD Progression Matures with Lessons for CKD Risk Factor Discovery.
    Oluwo O; Scialla JJ
    Clin J Am Soc Nephrol; 2021 Mar; 16(3):476-478. PubMed ID: 33055190
    [No Abstract]   [Full Text] [Related]  

  • 2. Time to target uric acid to retard CKD progression.
    Kumagai T; Ota T; Tamura Y; Chang WX; Shibata S; Uchida S
    Clin Exp Nephrol; 2017 Apr; 21(2):182-192. PubMed ID: 27339448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study.
    Oh TR; Choi HS; Kim CS; Bae EH; Ma SK; Sung SA; Kim YS; Oh KH; Ahn C; Kim SW
    Sci Rep; 2019 Apr; 9(1):6681. PubMed ID: 31040373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
    Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
    Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia.
    Tsuji T; Ohishi K; Takeda A; Goto D; Sato T; Ohashi N; Fujigaki Y; Kato A; Yasuda H
    Clin Exp Nephrol; 2018 Dec; 22(6):1300-1308. PubMed ID: 29700702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum uric acid level as an indicator for CKD regression and progression in patients with type 2 diabetes mellitus-a 4.6-year cohort study.
    Chang YH; Lei CC; Lin KC; Chang DM; Hsieh CH; Lee YJ
    Diabetes Metab Res Rev; 2016 Sep; 32(6):557-64. PubMed ID: 26590369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis.
    Bose B; Badve SV; Hiremath SS; Boudville N; Brown FG; Cass A; de Zoysa JR; Fassett RG; Faull R; Harris DC; Hawley CM; Kanellis J; Palmer SC; Perkovic V; Pascoe EM; Rangan GK; Walker RJ; Walters G; Johnson DW
    Nephrol Dial Transplant; 2014 Feb; 29(2):406-13. PubMed ID: 24042021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
    Lee JW; Lee KH
    Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
    Sezai A; Soma M; Nakata K; Osaka S; Ishii Y; Yaoita H; Hata H; Shiono M
    J Cardiol; 2015 Oct; 66(4):298-303. PubMed ID: 25649025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease.
    Sakai Y; Otsuka T; Ohno D; Murasawa T; Sato N; Tsuruoka S
    Ren Fail; 2014 Mar; 36(2):225-31. PubMed ID: 24152124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
    Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM
    Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of allopurinol on the glomerular filtration rate of children with chronic kidney disease.
    Ghane Sharbaf F; Assadi F
    Pediatr Nephrol; 2018 Aug; 33(8):1405-1409. PubMed ID: 29549464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease.
    Tsuruta Y; Mochizuki T; Moriyama T; Itabashi M; Takei T; Tsuchiya K; Nitta K
    Clin Rheumatol; 2014 Nov; 33(11):1643-8. PubMed ID: 25048744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
    Chou HW; Chiu HT; Tsai CW; Ting IW; Yeh HC; Huang HC; Kuo CC;
    Nephrol Dial Transplant; 2018 Sep; 33(9):1620-1627. PubMed ID: 29165620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD.
    Srivastava A; Kaze AD; McMullan CJ; Isakova T; Waikar SS
    Am J Kidney Dis; 2018 Mar; 71(3):362-370. PubMed ID: 29132945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
    Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC
    Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study.
    Rodenbach KE; Schneider MF; Furth SL; Moxey-Mims MM; Mitsnefes MM; Weaver DJ; Warady BA; Schwartz GJ
    Am J Kidney Dis; 2015 Dec; 66(6):984-92. PubMed ID: 26209544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor?
    Nashar K; Fried LF
    Adv Chronic Kidney Dis; 2012 Nov; 19(6):386-91. PubMed ID: 23089273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum uric acid variability increases the risk of postoperative chronic kidney disease in patients with renal cell carcinoma after radical nephrectomy.
    Li X; Li Z; Wu X; Zhang M; Xu L; Hao X; Li H; Qiao P; Wang W
    Urol Oncol; 2021 Aug; 39(8):500.e1-500.e7. PubMed ID: 34187751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uric acid as a target of therapy in CKD.
    Jalal DI; Chonchol M; Chen W; Targher G
    Am J Kidney Dis; 2013 Jan; 61(1):134-46. PubMed ID: 23058478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.